Press Releases Year None20262025202420232022202120202019 June 4, 2026 LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit May 27, 2026 LeonaBio to Participate in Upcoming Medical and Industry Meetings in June May 7, 2026 LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update May 7, 2026 LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D. April 23, 2026 LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer April 21, 2026 Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data March 26, 2026 LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update February 3, 2026 LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer January 9, 2026 Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” December 18, 2025 Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 156
Year None20262025202420232022202120202019 June 4, 2026 LeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development Summit May 27, 2026 LeonaBio to Participate in Upcoming Medical and Industry Meetings in June May 7, 2026 LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update May 7, 2026 LeonaBio Enhances Board of Directors with Appointments of Fred Callori, J.D., Natalie Holles and Peter B. Silverman, J.D. April 23, 2026 LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer April 21, 2026 Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data March 26, 2026 LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update February 3, 2026 LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer January 9, 2026 Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” December 18, 2025 Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 156
